Shares of Health Information Services company 10x Genomics climbed 5.9% this afternoon. Here are some quick facts to get you started if you are interested in the stock:
-
10x Genomics has logged a -70.4% 52 week change, compared to -16.6% for the S&P 500
-
TXG has an average analyst rating of buy and is -19.66% away from its mean target price of $49.8 per share
-
Its trailing earnings per share (EPS) is $-0.8, which brings its trailing Price to Earnings (P/E) ratio to -49.9. The Healthcare sector's average P/E ratio is 13.21
-
The company's forward earnings per share (EPS) is $-1.18 and its forward P/E ratio is -33.9
-
The company has a Price to Book (P/B) ratio of 5.9 in contrast to the Healthcare sector's average P/B ratio is 4.07
-
The current ratio is currently 6.8, which consists in its liquid assets divided by any liabilities due within in the next 12 months
-
The company's free cash flow for the last fiscal year was $-122,651,000.00 and the average free cash flow growth rate is -1498.2%
-
10x Genomics's revenues have an average growth rate of 42.8% with operating expenses growing at 48.2%. The company's current operating margins stand at -10.8%